Last reviewed · How we verify
US-DARZALEX FASPRO®-Rd — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
US-DARZALEX FASPRO®-Rd (US-DARZALEX FASPRO®-Rd) — Shanghai Henlius Biotech.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| US-DARZALEX FASPRO®-Rd TARGET | US-DARZALEX FASPRO®-Rd | Shanghai Henlius Biotech | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- US-DARZALEX FASPRO®-Rd CI watch — RSS
- US-DARZALEX FASPRO®-Rd CI watch — Atom
- US-DARZALEX FASPRO®-Rd CI watch — JSON
- US-DARZALEX FASPRO®-Rd alone — RSS
Cite this brief
Drug Landscape (2026). US-DARZALEX FASPRO®-Rd — Competitive Intelligence Brief. https://druglandscape.com/ci/us-darzalex-faspro-rd. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab